After five years, 60% of patients with a specific type of lung cancer treated with Pfizer's lorlatinib were still alive without their disease progressing, a dramatic finding compared to just 8% on the older therapy, crizotinib, according to cancer. The median progression-free survival for the lorlatinib group was not reached after five years of follow-up, according to pubmed, offering significant hope for ALK-positive non-small cell lung cancer (NSCLC) patients. While many cancer therapies offer incremental gains, lorlatinib delivers a dramatic, sustained benefit over the previous standard, redefining expectations for targeted therapies in ALK-positive NSCLC. These robust 5-year CROWN trial results position lorlatinib as the preferred first-line treatment for ALK-positive NSCLC, significantly improving patient outcomes and setting a new benchmark for targeted therapies that challenges the industry to match its long-term efficacy.

A New Benchmark for Progression-Free Survival

  • The 5-year PFS for the lorlatinib group was 60% (95% CI, 51 to 68), according to pubmed.
  • The 5-year PFS for the crizotinib group was 8% (95% CI, 3 to 14), according to pubmed.
  • Median PFS with crizotinib was 9.1 months (95% CI, 7.4 to 10.9), according to pubmed.

This stark quantitative comparison reveals lorlatinib's profound impact, extending progression-free life for patients by multiple years compared to older therapies. The fact that the median progression-free survival for the lorlatinib group was not reached after five years is a rarity in advanced cancer treatment. This long-term efficacy makes continued first-line use of crizotinib clinically questionable.

Targeted Efficacy, Including Brain Metastases

The CROWN trial confirmed lorlatinib's targeted effectiveness, showing significantly longer progression-free survival for ALK-positive NSCLC patients on first-line lorlatinib, according to nejm. Crucially, lorlatinib also achieved high intracranial response in patients with baseline brain metastases after 5 years, according to ascopubs. This ability to control disease in the brain is vital, as brain metastases are a devastating aspect of ALK-positive NSCLC where many other therapies fail. Any future first-line ALK inhibitor must demonstrate superior or comparable brain penetration and efficacy to gain market acceptance, as lorlatinib offers a comprehensive solution to this critical challenge.